title: Shelved 4-1BB Antibodies Make Comeback.
abstract: New trials are reexamining 4-1BB antibodies for a variety of cancers. Development of the drugs had stalled due to concerns about toxicity, but recent studies in animals, as well as early-phase trials, suggest that new formulations of the drugs may be less toxic-and potentially more potent-when combined with other therapies.
authors.forename: Janet
authors.initials: J
authors.lastname: Colwell
mesh_terms: D000911:Antibodies, Monoclonal / Q000494:pharmacology* / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy* / Q000378:metabolism* / Q000473:pathology; D016896:Treatment Outcome; D053261:Tumor Necrosis Factor Receptor Superfamily, Member 9 / Q000037:antagonists & inhibitors* / Q000378:metabolism
chemical_list: D000911:Antibodies, Monoclonal; D053261:Tumor Necrosis Factor Receptor Superfamily, Member 9